Radiochemotherapy with daily concomitant and adjuvant one week on/one week off temozolomide plus indomethacin in newly diagnosed glioblastoma: A phase II trial
| Autor: | Ulrich Herrlinger, M. Weller, Michael Bamberg, Dorothee Wiewrodt, A. von Deimling, Markus Weiler, J. Schuth, Christian Hartmann, W Wick |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Cancer Research
medicine.medical_specialty Leukopenia Temozolomide Anemia business.industry medicine.medical_treatment Common Terminology Criteria for Adverse Events medicine.disease Gastroenterology Surgery Radiation therapy Oncology Concomitant Internal medicine Toxicity medicine Clinical endpoint medicine.symptom business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 26:2044-2044 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2008.26.15_suppl.2044 |
| Popis: | 2044 Background: To evaluate toxicity and efficacy of an intensified schedule of temozolomide plus indomethacin in addition to standard radiotherapy plus concomitant temozolomide in patients (pts) with newly diagnosed glioblastoma. Methods: This trial (UKT-05) enrolled 41 pts treated with pre-irradiation temozolomide at 150 mg/m² (one week on/one week off), radiotherapy with concomitant temozolomide (50 mg/m²), maintenance temozolomide starting at 150 mg/m² according to an intensified one week on/one week off schedule, plus maintenance indomethacin (25 mg bid) treatment. The primary endpoint was median progression-free survival (PFS). O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation was assessed by methylation-specific PCR in 39 (95.1%) pts. Results: The median follow-up interval is 15.3 months (minimum, 9.4 months). Hematologic grade 3/4 toxicities according to the Common Terminology Criteria for Adverse Events (CTCAE; v3.0) were: anemia (3/41, 7%), leukopenia (9/41, 22%), lymphope... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|